new currency in the usa, Featured

Apple is reported to cooperate with Broadcom to develop AI chips, and TSMC's advanced process will welcome big orders again. On December 13, it was reported that Apple intends to invest in self-developed AI chips, jointly develop them with Broadcom, and produce them in TSMC's 3 nm process, and mass-produce them in 2026. The legal person is optimistic that after the development of Apple's self-developed AI chip is completed, the investment is expected, and TSMC's advanced process will usher in another big order. It is understood that Apple's current A-series processors for iPhone and M-series processors for Mac all adopt self-developed strategies, and are exclusively manufactured by TSMC. The legal person believes that once Apple's self-developed chips are extended to AI chips, the cooperation with TSMC will be closer. (Taiwan Province Economic Daily)CITIC Securities: Short-term white horse style may be dominated by stages due to compensatory growth and repair. CITIC Securities Research Report pointed out that looking forward to 2025, we expect that the market style will gradually switch from individual investors to institutional investors, and ETF will become an important configuration tool. We believe that the construction of ETF portfolio should mainly depend on the judgment of style rotation and timing. We believe that in the short term, Politburo meeting of the Chinese Communist Party and the Central Economic Work Conference will once again confirm the policy inflection point, which is expected to boost institutional investors' risk appetite, and the white horse style may prevail in stages due to compensatory growth and repair. However, in the large-cycle environment, it is still unable to meet the conditions for the continued dominance of white horse stocks, and it is necessary to continue to observe the price signals and policies.The leading enterprises in the quantum science and technology sector are competing for layout. Recently, the quantum science and technology sector has been active. Since September 24, the concept index of the straight flush quantum science and technology has risen by more than 60%, and the stock prices of many stocks have doubled. Among A-share listed companies, many companies including China Mobile, China Telecom, Guo Dun Quantum, Hexin Instrument, Guoxin Technology and Geer Software have already laid out in the field of quantum technology. In terms of future market potential, ICVTA&K, a scientific and technological consulting organization, predicts that in 2023, the overall market size of the global quantum industry may reach 7.24 billion US dollars. However, the current quantum technology industry is still in the stage of research and development and industrial exploration. Taking quantum computing as an example, Guo Dun Quantum said in a survey conducted by an organization on November 15th that quantum computers have only achieved quantum superiority in some specific problems at present, and it is estimated that it will take about 5 to 10 years to surpass classical computing power in practical and valuable problems in the future. (Economic Information Daily)

A delegation of Japanese young and middle-aged military officers visited China. Today, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said that at the invitation of China Institute of International Strategic Studies, a delegation of Japanese young and middle-aged military officers will visit China from November 26th to December 4th. The Sino-Japanese exchange program for young and middle-aged officers began in 2001, which played an important role in enhancing understanding and trust between the defense departments of the two countries. We are willing to work with Japan to continue to promote mutual visits and exchanges and provide positive energy for the improvement and development of bilateral relations.Yingsi Intelligent announced that it had received a milestone payment of $10 million from Exelixis. On December 13th, Yingsi Intelligent, a biomedical technology company, announced that based on the progress made in the clinical stage of XL309(ISM3091) project, the company had recently received the first clinical milestone payment from Exelixis, with a total amount of $10 million.CICC: Cloud and terminal AI landing In 2025, the localization of semiconductors and components ushered in a new cycle. According to CICC's research report, in 2024, semiconductors and components as a whole were in the upward stage of prosperity. It is expected that inventory, supply and demand will stabilize in 2025, and AI cloud and terminal demand will land, and domestic elements will usher in a new cycle. It is expected that in 2025, the AI ​ ​ replacement tide is expected to accelerate the downstream demand growth of the semiconductor design sector. We are optimistic about the demand expansion of cloud and end-side computing chips driven by AI, and the alpha level of individual stocks is optimistic about the pull of product structure expansion on the performance of related companies, and it is suggested to pay attention to the investment opportunities brought by mergers and acquisitions for some tracks. It is expected that the supply and demand of chip manufacturing will approach a balance in 2025, and the capacity utilization rate will remain at a reasonable level; Among them, the research and development of advanced process manufacturing is expected to continue to advance, driving the development of equipment, parts, materials and design tools.

Guotai Junan: It is suggested that the beauty care sector with product and channel changes and flexibility should be optimized from the bottom up. Guotai Junan said that after the pressure of consumption in 2022 and the destocking of consumers in 2023, the beauty consumption will return to the normal purchase cycle in 2024, and the industry prosperity will improve month-on-month, and the double-digit growth of online beauty will be achieved. However, after the channel dividend subsided, the platform traffic and price competition became fierce, and the brand differentiation further intensified. Relying on the product innovation and channel operation ability brought by organizational efficiency, the performance of domestic products in the head is still bright, and the rise of new domestic products has spread from beauty cosmetics to personal care. Looking forward to 2025, the market risk appetite will be significantly restored. Because of its many changes and the rising trend of domestic products as a whole, the American nursing sector has obvious growth attributes and significantly benefited from its style. Brand differentiation in the fundamental dimension has intensified, and it is suggested that the flexible target with product and channel changes should be optimized from bottom to top.Yuejiang: It is planned to sell about 40 million H shares globally through the IPO of Hong Kong stocks. It is expected to be listed on the Hong Kong Stock Exchange on December 23, and Yuejiang announced on the Hong Kong Stock Exchange on December 13 that the company plans to sell about 40 million H shares globally, with Hong Kong public offering accounting for 5% and international offering accounting for 95%. The offer price will not be higher than HK$ 20.80 per offering share, and it is currently expected to be not lower than HK$ 18.80 per offering share, with 200 shares per lot. It is expected that the shares will start trading on the Stock Exchange at 9: 00 am on Monday, December 23, 2024, Hong Kong time.Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.